Prot #GS-US-595-6184: A Randomized, Open-label, Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician’s Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and N

Project: Research project

Project Details

StatusActive
Effective start/end date9/27/249/27/27

Funding

  • PPD Development (Prot #GS-US-595-6184 // Prot #GS-US-595-6184)
  • Gilead Sciences, Inc (Prot #GS-US-595-6184 // Prot #GS-US-595-6184)